Considering that about 30% of the enrolled carriers developed breast cancer, these findings emphasize the need for increased awareness about breast cancer surveillance and providing more affordable screening options for BRCA1/2 mutation carriers. This evidence concerns the gene BRCA1 and breast cancer.